Calciphylaxis in End-Stage Renal Disease: A Rare Condition With High Mortality

Ramya Bachu ¹, Tanvi H. Patel ¹, Stefan Hemmings ²

¹. Internal Medicine, Baptist Health–University of Arkansas for Medical Sciences (UAMS), North Little Rock, USA ². Nephrology, Baptist Health–University of Arkansas for Medical Sciences (UAMS), North Little Rock, USA

Corresponding author: Ramya Bachu, ramyabachu1@gmail.com

Abstract
Calciphylaxis is a rare but life-threatening condition, seen in patients with end-stage renal disease (ESRD) on renal replacement therapy. Its pathogenesis is not completely known, but microvascular calcification and thrombosis are considered the likely processes. It is characterized by significant morbidity due to severe pain and nonhealing wounds with frequent hospitalizations. Sepsis is the most common cause of mortality with more than 50% of patients dying within the first year after diagnosis. Optimal management requires a multidisciplinary approach. We describe a case of a 66-year-old female with ESRD on hemodialysis (HD) who presented with severe progressive calciphylaxis wounds on both lower extremities and died within two months after diagnosis. She had multiple admissions in the past for cellulitis when she presented with swelling in the legs and chronic wounds. Our goal is to increase awareness among physicians to include calciphylaxis in their differential diagnosis when treating ESRD patients with significant risk factors to detect it early and prevent morbidity and mortality.

Introduction
Calciphylaxis or calcific uremic arteriolopathy is a rare but life-threatening condition that is characterized by painful skin lesions including indurated plaques, livedo reticularis, and necrosis that can progress to penetrating ulceration with secondary wound infection. It is associated with high morbidity and mortality, with a reported one-year mortality of 30-80% [1]. Most commonly, it affects patients with end-stage renal disease (ESRD) and can occur in both peritoneal and hemodialysis (HD) patients. Risk factors include hyperphosphatemia, hypercalcemia, hyper- and hypoparathyroidism, hypercoagulability, diabetes mellitus, female sex, white race, autoimmune diseases, obesity, and warfarin use [2]. Here, we describe a case of a 66-year-old female with ESRD on hemodialysis (HD) who presented with severe progressive calciphylaxis wounds on lower extremities and died within two months after diagnosis. The purpose of this case report was to increase awareness among physicians to include calciphylaxis in their differential diagnosis while treating ESRD patients since this condition is associated with high mortality.

Case Presentation
A 66-year-old African American woman presented to the hospital with shortness of breath, worsening pain, and swelling in the legs. Her medical comorbidities were significant for obesity (with BMI >40), diabetes mellitus type 2, hypertension, hyperlipidemia (HLD), gout, ESRD on hemodialysis (HD) for more than two years, warfarin use for arterio-venous graft clotting in the past, endometrial cancer and iron deficiency anemia. On examination, she had a longitudinal necrotic, indurated wound on the left lateral thigh which was tender and warm to touch with slight erythema (Figure 1). Another indurated wound was noted on the right medial thigh. She had these wounds for a few months, however, she did not seek any medical treatment. She had multiple admissions in the past for swelling in the legs and wounds on the lower extremities and was treated with antibiotics for possible cellulitis. She was admitted for wound infection management.
Her labs were significant for an elevated white blood cell count of 20,100, anemia with hemoglobin 8.6 g/dL, serum creatinine 11.4 mg/dL, parathyroid hormone (PTH) level of 634 pg/mL, calcium 11.9 mg/dL, and phosphorus 10.7 mg/dL (she was not on any phosphate binders on admission). She was empirically started on IV vancomycin for possible cellulitis. A wound care specialist consultation was sought and the left leg wound was debrided and wound cultures were taken. There was a high suspicion of calciphylaxis, given her history of ESRD on dialysis, hyperparathyroidism, warfarin use, hyperphosphatemia, hypercalcemia, and female sex. A skin biopsy was performed. Warfarin was discontinued as it is one of the strong risk factors for calciphylaxis. Aggressive intervention for her hyperphosphatemia with a phosphate binder (sevelamer carbonate) was started. The skin biopsy showed calcified vessels, focal necrosis, and acute inflammation, confirming calciphylaxis. The wound was confirmed to have a polymicrobial infection and was covered with appropriate antibiotics. She was stable for discharge to rehab with sodium thiosulphate therapy three times a week with dialysis. Hyperbaric oxygen therapy was recommended but was declined.

Two weeks later, the patient was followed up in the wound clinic with slight worsening of the wounds and appropriate debridement was performed (Figure 2). She was readmitted to the hospital one month later, with altered mental status, acute respiratory failure with hypoxia, and multiple calciphylaxis wounds on the abdomen, legs, and right breast (Figures 3, 4).
FIGURE 2: Left lateral thigh wound in the wound clinic after discharge from the hospital
FIGURE 3: Left lateral thigh wound during the second admission
Her wounds were adequately debrided and she was started on antibiotics. After some improvement, goals of care were discussed with the patient and she elected palliative and comfort measures with no further invasive surgical or medical interventions; she died later that month.

Discussion
Calciphylaxis or calcific uremic arteriolopathy is a rare but life-threatening condition that is characterized by painful skin lesions including indurated plaques, livedo reticularis, and necrosis that can progress to penetrating ulceration with secondary wound infection. It is associated with high morbidity and mortality, with a reported one-year mortality of 30–80% [1]. Most commonly, it affects patients with ESRD and can occur in both peritoneal and HD patients. Risk factors include hyperphosphatemia, hypercalcemia, hyper- and hypoparathyroidism, hypercoagulability, diabetes mellitus, female sex, white race, autoimmune diseases, obesity, and warfarin use [2]. The pathogenesis of calciphylaxis remains unclear but microvascular calcification and thrombosis are considered likely processes in calciphylaxis development. Histopathologically, the pannicular small- and medium-sized arteries and arterioles typically show calcification of the media, intimal hyperplasia, endovascular fibrosis, and intravascular thrombosis resulting in an obliteratorative vasculopathy causing painful ischemic skin lesions [1,2].

Severe pain, which is believed to be both ischemic and neuropathic in origin, is a nearly universal feature of
Calciphylaxis is a rare but life-threatening condition common in patients with end-stage renal disease on renal replacement therapy. Diagnosis requires a high degree of suspicion based on clinical features and can be supported by skin biopsy. Physicians should be cautious when treating patients with poor wound healing and refractory mineral bone disease, the adequacy of dialysis should be investigated. Aggressive dialysis in the form of increased frequency or duration should be considered. Calcium supplements, high dialysate calcium baths, and vitamin D preparations should be avoided. Surgical parathyroidectomy is indicated in patients with refractory hyperparathyroidism but the studies showed controversies [8,9]. A nutrition consult should be obtained to address protein-energy malnutrition.

Conclusions

Calciphylaxis is a rare but life-threatening condition commonly seen in patients with end-stage renal dialysis on renal replacement therapy. Diagnosis requires a high degree of suspicion based on clinical features and can be supported by skin biopsy. Physicians should be cautious when treating patients with ESRD for cellulitis and chronic wounds, and calciphylaxis should be in their differential diagnosis. Early identification of such patients is crucial to allow prompt treatment and to avoid the high morbidity and mortality associated with calciphylaxis.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Weening RH, Sewell LD, Davis MD, McCarthy JT, Pittelflow MR: Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007, 56:569-79. 10.1016/j.jaad.2006.08.065
2. Chang JJ: Calciphylaxis: diagnosis, pathogenesis, and treatment. Adv Skin Wound Care. 2019, 32:205-15. 10.1097/01.SAW.0000544453.14002.13
3. Baby D, Upadhyay M, Joseph MD, Asopa SJ, Choudhury RK, Raigup G, Gupta S: Calciphylaxis and its diagnosis: a review. J Family Med Prim Care. 2019, 8:2765-7. 10.4103/jfmpc.jfmpc_588_19
4. Nigwekar SU, Krohsinsky D, Nazarian RM, et al.: Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015, 66:135-46. 10.1053/j.ajkd.2015.01.034
5. Kusajima EG, Yamamoto Y, Murao N: Wound care for calciphylaxis: a novel approach for wound management with negative pressure wound therapy with instillation and dwell time. Int J Surg Wound Care. 2020, 1:20-6. 10.3674/ijswc.1.1.20
6. Tailor Y, Armour D, Preston-Hsu E: A retrospective analysis of treatment of wounds caused by calciphylaxis: hyperbaric oxygen therapy with and without sodium thiosulfate. Ann Phys Rehabil Med. 2018, 61:10.1016/j.rehab.2018.05.896
7. Yu Z, Gu L, Pang H, Fang Y, Yan H, Fang W: Sodium thiosulfate: an emerging treatment for calciphylaxis in...
8. Arch-Ferrer JE, Beenken SW, Rue LW, Bland KI, Diethelm AG: Therapy for calciphylaxis: an outcome analysis. Surgery. 2005, 134:941-4. 10.1016/j.surg.2005.07.001

9. Karmegam S, Shetty A: Calciphylaxis after parathyroidectomy. Hemodial Int. 2017, 21:62-6. 10.1111/hdi.12599